靶向治疗时代重新评估慢性淋巴细胞白血病国际预后指数
在991例接受靶向药物一线治疗和1256例接受化学免疫治疗的慢性淋巴细胞白血病患者中评估CLL-IPI。靶向治疗组中位观察40.5个月,CLL-IPI仍可预测无进展生存,但对总生存的预测作用似乎减弱;匹配分析显示靶向治疗在全部风险组中PFS优于化学免疫治疗。
要点
- 靶向治疗组3年PFS按CLL-IPI低、中、高、极高危分别为96.5%、87.6%、82.4%、78.7%。
- 靶向治疗组3年OS按风险组为100%、96%、93.9%、89.4%,相邻风险组间无差异。
- 匹配分析中靶向治疗在全部风险组的PFS及除低危外各组的OS均优于化学免疫治疗。
核心结论
- CLL-IPI在接受靶向药物治疗的患者中仍保持对PFS的预后价值,但其对生存的预测作用似乎减弱。
- 靶向治疗较化学免疫治疗显示出更好的结局,凸显其在不同风险组中的有效性。
- 研究结果支持在CLL治疗演变中持续评估预后工具。
研究设计与样本
- 评估CLL-IPI的预后价值,纳入一线接受靶向药物(n=991)或化学免疫治疗(n=1256)的CLL患者。
- 靶向治疗组中位观察时间40.5个月,化学免疫治疗组中位观察时间66.9个月。
- 进行了匹配配对分析,靶向治疗组n=812,化学免疫治疗组n=812。
- 相关试验注册于ClinicalTrials.gov,注册号包括NCT02345863、NCT02401503、NCT02689141、NCT02445131、NCT02758665、NCT02950051、NCT02242942、NCT00262782、NCT00281918和NCT01010061。
主要发现
- 靶向治疗组3年PFS率按CLL-IPI低、中、高、极高危分别为96.5%、87.6%、82.4%、78.7%;中危vs低危和高危vs中危之间观察到差异,极高危vs高危之间未观察到差异。
- 靶向治疗组中β2-微球蛋白、免疫球蛋白重链可变区(IGHV)状态和TP53状态各自保留对PFS的预后价值。
- 靶向治疗组3年OS率按CLL-IPI低、中、高、极高危分别为100%、96%、93.9%、89.4%,相邻风险组间无差异;年龄、Binet分期、β2-微球蛋白和TP53状态各自保留对OS的预后价值。
- 化学免疫治疗组3年PFS率按CLL-IPI低、中、高、极高危分别为78.1%、51.4%、40.1%、16.5%;相应3年OS率分别为97.4%、93.1%、81.8%、57.3%。
- 匹配配对分析显示,靶向治疗(n=812)vs化学免疫治疗(n=812)在全部风险组中显示PFS差异,在除低危患者外的所有组中显示OS差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated the chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) in patients with CLL treated first line with targeted drugs (n = 991) or chemoimmunotherapy (n = 1256). With a median observation time of 40.5 months, the 3-year progression-free survival (PFS) rates for targeted drug-treated patients varied by CLL-IPI risk group: 96.5% (low), 87.6% (intermediate), 82.4% (high), and 78.7% (very high). Differences between consecutive CLL-IPI risk groups were observed for intermediate vs low and high vs intermediate, but not very high vs high. CLL-IPI factors β2-microglobulin, immunoglobulin heavy variable (IGHV) status, and TP53 status each retained prognostic value for PFS. The 3-year overall survival (OS) rates by CLL-IPI risk groups were 100%, 96%, 93.9%, and 89.4%, respectively, with no differences between consecutive risk groups. Age, Binet stage, β2-microglobulin, and TP53 status each retained prognostic value for OS. In chemoimmunotherapy patients (median observation time, 66.9 months), 3-year PFS rates for CLL-IPI risk groups were 78.1%, 51.4%, 40.1%, and 16.5%, respectively; corresponding 3-year OS rates were 97.4%, 93.1%, 81.8%, and 57.3%. In a matched-pair analysis, PFS differences in targeted therapies (n = 812) vs chemoimmunotherapy (n = 812) across all risk groups and OS differences in all but patients at low risk were demonstrated. The CLL-IPI maintains its prognostic value in predicting PFS outcomes with targeted drugs, but its impact in predicting survival appears diminished. Targeted therapies showed enhanced outcomes over chemoimmunotherapy, highlighting their effectiveness across various risk groups. Our findings support ongoing assessment of prognostic tools in CLL treatment evolution. These trials were registered at www.ClinicalTrials.gov as #NCT02345863, #NCT02401503, #NCT02689141, #NCT02445131, #NCT02758665, #NCT02950051, #NCT02242942, #NCT00262782, #NCT00281918, and #NCT01010061.
引用
- Langerbeins P, Giza A, Robrecht S, et al. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies. Blood. 2024. PMID: 38620092. doi:10.1182/blood.2023022564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。